Viridian Therapeutics
VRDN
51 hedge funds and large institutions have $37.4M invested in Viridian Therapeutics in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 8 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
0.31% less ownership
Funds ownership: 3.17% → 2.86% (-0.31%)
9% less funds holding
Funds holding: 56 → 51 (-5)
16% less capital invested
Capital invested by funds: $44.5M → $37.4M (-$7.08M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$212K |
| 2 |
6CM
683 Capital Management
New York
|
+$208K |
| 3 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
+$86.7K |
| 4 |
D.E. Shaw & Co
New York
|
+$80.1K |
| 5 |
State Street
Boston,
Massachusetts
|
+$67.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.75M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.17M |
| 3 |
SG Americas Securities
New York
|
-$301K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$252K |
| 5 |
Morgan Stanley
New York
|
-$204K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $1K | -$33K | -730 | -98% |
|
|
SB
52
Samsara BioCapital
Palo Alto,
California
| – | -$2.75M | -60,606 | Closed |
|
|
OM
53
Opaleye Management
Boston,
Massachusetts
| – | -$1.17M | -25,667 | Closed |
|
|
54
SG Americas Securities
New York
| – | -$301K | -6,622 | Closed |
|
|
OAM
55
Oxford Asset Management
Oxford,
United Kingdom
| – | -$252K | -5,539 | Closed |
|
|
BWP
56
BSW Wealth Partners
Boulder,
Colorado
| – | -$67K | -1,482 | Closed |
|
57
Citadel Advisors
Miami,
Florida
| – | -$55K | -1,226 | Closed |
|
58
US Bancorp
Minneapolis,
Minnesota
| – | -$3K | -67 | Closed |
|
|
PHK
59
Point72 Hong Kong
Hong Kong
| – | -$1K | -15 | Closed |
|
VRDN Hedge Fund Activity: Q1 2019 in Review
51 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2019, worth a combined $37.4M — down 16% from $44.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VRDN and 3 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $212K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $2.75M sold.
- 51 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2019, down from 56 in Q4 2018.
- Funds reported $37.4M of Viridian Therapeutics stock for Q1 2019, down 16% quarter-over-quarter.
- 3 funds opened new Viridian Therapeutics positions in Q1 2019 and 8 closed out, a net change of -5 holders.
- The largest Viridian Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $212K added.
- The largest Viridian Therapeutics seller in Q1 2019 was Samsara BioCapital, an estimated $2.75M sold.
Based on aggregated 13F filings for Q1 2019.